Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lodde

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Translational Medicine|May 12, 2025
Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsKatarzyna Borys, Georg Lodde, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
Journal of Medical Internet Research|July 2, 2026
Extracting Medical Information From Unstructured Clinical Text Using Large Language Models to Enhance Health Care Interoperability: Proof-of-Concept StudyBahadır Eryılmaz, Kamyar Arzideh, Mikel Bahn, et al.
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2021
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyAnne Zaremba, Georg Lodde, Rajmohan Murali, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
Research Square|June 29, 2026
Challenges in AI Based Tumor Board Case Summarization and RecommendationsWen-Wai Yim, Hendrik Damm, Tabea M G Pakull, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal of Cancer Research and Clinical Oncology|May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspectiveKatharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Translational Medicine|May 12, 2025
Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsKatarzyna Borys, Georg Lodde, Elisabeth Livingstone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyPhilipp Jansen, Wolfgang Galetzka, Carl M Thielmann, et al.
Journal of Medical Internet Research|July 2, 2026
Extracting Medical Information From Unstructured Clinical Text Using Large Language Models to Enhance Health Care Interoperability: Proof-of-Concept StudyBahadır Eryılmaz, Kamyar Arzideh, Mikel Bahn, et al.
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2021
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyAnne Zaremba, Georg Lodde, Rajmohan Murali, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
Research Square|June 29, 2026
Challenges in AI Based Tumor Board Case Summarization and RecommendationsWen-Wai Yim, Hendrik Damm, Tabea M G Pakull, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal of Cancer Research and Clinical Oncology|May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspectiveKatharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Pageof 4